



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.) INDIA.

Tel. : (0731) 2517677 E-mail : beryldrugs25@yahoo.com **CIN : L02423MP1993PLC007840**

Date: 13th March, 2018

To,
The DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sir/ Madam,

This is with reference to your mail dated 9th March, 2018, Please find attached the Unaudited Financial Results for the quarter ended 31st December, 2017 exactly as per Schedule III of Companies Act, 2013. There is only addition of two rows i.e (14) other comprehensive income and (15) total comprehensive income in the revised report. Further there is no change in any figure or data from the results already submitted. Please take the attached Financials on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

Ashish Baraskar
Chief Financial Officer



BERYL DRUGS LIMITED
 Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
 Tel./ Fax 0731-3961510
 E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Submission of Unaudited/ Audited Financial Result by Companies Other than Banks


Part I							(Rs in 000)
Statement of standalone / Consolidated / Audited Result for the Quarter/ year ended 31/12/2017							
Particulars	Quarter ended			Third Quarter ended	Year ended		
	3 months ended (31-12-2017)	Preceding 3 months ended (30-09-2017)	Corresponding 3 months ended in the previous year (31-12-2016)	Year to date figures for current period ended (31-12-2017)	Year to date figures for previous period ended (31-12-2016)	Previous year ended (31-03-2017)	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 Revenue From Operations							
Net sales or Revenue from Operations	36309.000	32184.000	25758.000	116963.000	86152.000	109936.000	
Other operating revenues	36.000	214.000	353.000	628.000	1266.000	2607.000	
Total Revenue from operations (net)	36345.000	32398.000	26111.000	117591.000	87418.000	112543.000	
2 Expenses							
(a) Cost of materials consumed	25732.000	22522.000	23204.000	74861.000	71603.000	69426.000	
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-119.000	1454.000	-3997.000	12240.000	-5926.000	-4459.000	
(d) Employee benefit expense	2084.000	1721.000	2894.000	5459.000	8011.000	9787.000	
(e) Finance costs	212.000	317.000	547.000	903.000	1610.000	2009.000	
(f) Depreciation and amortisation expense	1000.000	1000.000	1000.000	3000.000	3000.000	3776.000	
(g) Other Expenses	6112.000	4226.000	3354.000	17980.000	7352.000	30303.000	
Total expenses	35021.000	31240.000	27002.000	114443.000	85650.000	110842.000	
3 Profit (loss) from operations before exceptional and extraordinary items and tax	1324.000	1158.000	-891.000	3148.000	1768.000	1701.000	
4 Exceptional items	0.000	0.000	0.000	0.000	0.000	0.000	
5 profit (loss) before extraordinary items and tax	1324.000	1158.000	-891.000	3148.000	1768.000	1701.000	
6 Extraordinary items	0.000	4568.000	0.000	4568.000	0.000	0.000	
7 Profit (loss) before tax	1324.000	5726.000	-891.000	7716.000	1768.000	1701.000	
8 Tax Expense							
Current tax	300.000	300.000	0.000	920.000	400.000	873.000	
Deferred tax	0.000	0.000	0.000	0.000	0.000	-338.000	
Total Tax Expenses	300.000	300.000	0.000	920.000	400.000	535.000	
9 Net Profit (loss) for the period from continuing operations	1024.000	5426.000	-891.000	6796.000	1368.000	1166.000	
10 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000	
11 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000	
12 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000	
13 Net Profit (loss) for the Period	1024.000	5426.000	-891.000	6796.000	1368.000	1166.000	
14 Other comprehensive income	0.000	0.000	0.000	0.000	0.000	0.000	
15 Total Comprehensive Income	1024.000	5426.000	-891.000	6796.000	1368.000	1166.000	
16 Details of equity share capital							
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000	
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000	
17 Earnings per share							
i Basic earnings per share before extraordinary items	0.202	0.169	0.000	0.621	0.270	0.230	
ii Diluted earnings per share before extraordinary items	0.202	0.169	0.000	0.621	0.270	0.230	

- Notes :
- The Quarterly results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 09th Feb 2018. The Statutory Auditors have carried out a limited review of the results for the quarter ended Dec 31, 2017.
 - This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) PRESCRIBED UNDER SECTION 133 OF THE Companies Act, 2013, & other recognized accounting practices & policies to the extent applicable. Beginning from April 1st, 2017 company has for the first time adopted Ind AS with transition date of April 1st, 2017.
 - The Income from Operations is from one segment namely "Pharmaceutical Industry".
 - Previous period exp. have been regrouped / rearranged, wherever necessary.
 - Taxes and depreciation are calculated on proportionate basis on annual estimated basis.
 - The Ind AS compliant financial results, Pretaining to period ended Sep 30, 2016 have not been subject to limited review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
 - Reconciliation of Profit reported in accordance with previous Indian GAAP (IGAAP) to total comprehensive Income in accordance with Ind AS is given below:

Particulars	Corresponding 3 months ended in the previous year DEC 31, 2016 (Rs in 000)
Profit for the period as per I GAAP	1368.000
Amortization of Goodwill	0
Reclassification of net actuarial loss on defined obligation to other comprehensive income	0
Charge of group ESOP	0
Tax impact in Ind AS adjustment	0
Profit for the period as per Ind AS	1368.000
Other comprehensive income as per Ind AS	0
Total Comprehensive Income as per Ind AS	1368.000

For and behalf of the Board

Place : Indore
 Date : 13.03.2018



Sanjay Sethi
 Managing Director